Mitokinin
Developing compounds to improve mitochondrial health in neurodegenerative diseases like Parkinson’s.
In 2017 a single scientist began operations at MBC BioLabs. In the last six years, Mitokinin has received $110M in funding, were acquired by AbbVie for $655M in 2023 and are progressing into clinical trials – and this may be the first disease modifying treatment for Parkinson’s.